CEACAM5 and neoplasm: In assessing the treatment response of curcumin combination therapy, a phase I dose-escalation clinical trial showed that the maximal tolerated dose of curcumin (8000 mg/day) co-treated with docetaxel (100 mg/m2) recorded 5/8 patients had partial response (PR) and 3/8 patients had stable disease (SD), with a significant decrease in the tumor marker carcinoembryonic antigen (CEA) and VEGF biomarkers of metastatic breast cancer [168].